Thrive Earlier Detection Corp., a company dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care, together with Johns Hopkins University and Geisinger Health, today announced data from the landmark DETECT-A study. DETECT-A (Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing) is the first ever prospective, interventional study to use a blood test to screen for multiple types of cancers in a real-world population. The study was conducted by Johns Hopkins University and Geisinger and enrolled more than 10,000 women with no prior history of cancer. The purpose was to identify multiple cancer types in asymptomatic individuals using an early version of CancerSEEK developed in 2016 ("Thrive's blood test"). DETECT-A is the first study of a multi-cancer blood-based screening test to deliver results to physicians to manage patient care.
Cancer is the second leading cause of death in the United States with an estimated 600,000 people expected to die from the disease this year. Most of these cancers are often detected too late, and only after people start to experience symptoms. These "symptom-detected" cancers too frequently coincide with late stage, metastatic disease, and result in poor outcomes. However, when cancer is detected through screening, or are "screen-detected," the disease is often identified earlier when it can be more effectively treated, and in many cases even cured. Unfortunately, current standard-of-care screening tests, like mammography and colonoscopy, only detect less than 30% of all incident cancers. The DETECT-A study provides the first real-world evidence that we can significantly shift the paradigm from "symptom-detected" cancers to more "screen-detected" cancers via a multi-cancer blood-based test.
The key findings from this prospective, interventional study demonstrate the following:
- Thrive's blood test identified cancers in individuals without any history of the disease.
- Thrive's blood test more than doubled the number of cancers that were first "screen-detected." 25% of the women who were diagnosed with cancer were identified by current standard-of-care tests. By incorporating Thrive's blood test, the percentage of "screen-detected" cancers increased from 25% to 52%.
- Thrive's blood test identified cancers across 10 different organs, seven of which currently have no standard-of-care screening.
- Thrive's blood test can identify cancers prior to clinically evident metastasis. 65% of the cancers identified were localized or regional.
- Thrive's blood test is additive and complementary to standard-of-care and was incorporated into routine medical care without discouraging patients from engaging in other forms of screening.
- Thrive's blood test, in combination with imaging, minimized false positive results with 99.6% specificity.
- The study's workflow (blood test plus imaging) safely guided clinical follow-up in blood test-positive participants with zero adverse events.
"This study is a seminal moment in cancer screening that advances the entire field," said Christoph Lengauer, Ph.D., co-founder and chief innovation officer of Thrive. "For the first time, a blood test was utilized in a real-world setting and was able to more than double the number of cancers first identified through screening methods. We learned that it can be both complementary to existing standard-of-care screening tools, and a significant benefit for many types of cancers like ovarian, appendix and kidney, which do not have any current screening modalities."
These data were published in Science and were presented today during the clinical plenary: Early Detection and CtDNA at the American Association for Cancer Research (AACR) Virtual Annual Meeting.
Prospective Interventional Study Design
The ability to identify multiple types of cancers through a blood draw is one of the most exciting advances in cancer diagnostics; however, prospective, interventional studies like DETECT-A are imperative to understand if a test can work in the real world. To date, retrospective and observational studies of blood-based multi-cancer tests have curated samples from participants who were already known to have cancer at the time of testing. Conversely, in DETECT-A, a prospective interventional study, participants were unaware of cancer at the time of enrollment and test results were reported to physicians and guided intervention.
DETECT-A enrolled 10,006 women with no prior history of cancer in a population with high adherence to standard-of-care cancer screening tests, such as mammography and colonoscopy. All participants were enrolled through the Geisinger Health System, enabling access to electronic medical records of participating individuals and minimizing loss to follow up.
DETECT-A utilized an early version of CancerSEEK that was developed in 2016, and analyzes 16 genes and nine proteins causatively linked to multiple types of cancer. Screening began with the analysis of a blood sample to identify potential abnormal values for at least one biomarker. Those with abnormal values were invited back for a confirmatory test to determine whether the identical biomarker was persistently abnormal and if appropriate, the individual was reviewed by a Multidisciplinary Review Committee. If a non-cancerous cause for the abnormal biomarker could not be identified, imaging was ordered. Patients with concerning imaging findings were referred to cancer specialists for further evaluation.
Thrive's blood test doubled the number of cancers first found through screening. Among the eligible participants, 96 women developed cancers: 26 of these were first identified by Thrive's blood test, 24 were first identified by standard-of-care screening methods, and 46 were first identified by symptoms or other means. Thrive's blood test detected cancers across ten different organs, including seven organs that do not have standard-of-care screening tools available. Notably, 65% of cancers detected by Thrive's blood test were identified as local or regional disease, allowing for earlier intervention and if indicated, surgery with intent to cure. Thrive's blood test's sensitivity was 27.1% across all cancers and 31.1% for the seven cancers with no screening options. Importantly, Thrive's blood test plus standard-of-care testing had a combined sensitivity of 52.1%, underscoring that a multi-cancer blood test is both a significant added benefit and complementary to standard-of-care screening tools.
Maintaining a high specificity thereby minimizing "false-positive" results is essential for a multi-cancer blood test. Screening with Thrive's blood test alone had a 98.9% specificity, and when combined with imaging had a specificity of 99.6%. Thrive's blood test plus imaging safely and efficiently guided clinical follow-up in blood test-positive participants with zero adverse events. Holistically, in this asymptomatic population with a cancer incidence of approximately 1%, Thrive's blood test plus imaging resulted in a positive predictive value (PPV) of 40.6%, which is considerably higher than the PPV of existing single-cancer screening tests available today.
"Through this first-ever interventional study, the teams at Johns Hopkins University, Geisinger and Thrive have forged a new path and advanced the field of blood-based earlier cancer detection," said David J. Daly, chief executive officer of Thrive. "Thrive is now one step closer to realizing our vision of providing a comprehensive approach to cancer screening, helping to shift the paradigm so that in the future, most cancers can be identified through earlier detection when there is the greatest opportunity for cure."
About Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive's integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences and Gamma3. For more information, please visit http://www.thrivedetect.com.
1 Lennon et al. Science First Release, 2020